ACTRN12613000158763.

Study name	Evaluating treatment efficacy of citalopram, symbiotic, and mebeverine for children with functional abdominal pain
Methods	Randomised, double‐blind, placebo‐controlled trial
Participants	Children and adolescents aged 6 to 18 years with functional abdominal pain (FAP)
Interventions	Citalopram (10 mg/ day for 1 week and 20 mg/day for 3 weeks) or Mebeverine (135 mg twice daily) or Lactol tablet (150 million spores + 100 mg FOS twice daily) or placebo (twice daily) for 4 weeks
Outcomes	Primary outcomes: Clinical Global Impression‐Global Improvement (CGI‐I), Clinical Global Impression‐severity (CGI‐S) and Wong‐Baker Faces Pain Rating Score at 4 weeks. Secondary outcomes: CGI‐I, CGI‐S and Wong‐Baker Faces Pain Rating Score at 12 weeks after end of treatment
Starting date	November 2012 to December 2013
Contact information	Principal Investigator: Zahra Pourmoghaddas, Emam Hosein Children Hospital, Iran
Notes	anzctr.org.au Identifier: ACTRN12613000158763 Principal investigator was contacted, no response received.